EUCTR2019-001042-18-ES进行中（未招募）1 期
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma
illy SA0 个研究点目标入组 71 人开始时间: 2019年11月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- having a refractory/recurrent neuroblastoma
- •- patient must be between 2-21 years old
- •- must have demonstrated active disease
- •- providing a mandatory archival sample of tissue
- •- being able to swallow capsules
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 70
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- having untreated central nervous system metastases
- •- serious concomitant disorder: e.g. active infection, GI disorder, profound immune suppression
- •- malabsorption
- •- serious heart condition: congestive heart failure, arrhythmias, valvulopathy
- •- body surface area (BSA) < 0.5 square meter
- •- pregnant or breastfeeding
- •- have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C
研究者
相似试验
进行中（未招募）
1 期
A Phase 1 Study of LY3295668 Erbumine Monotherapy and in Combination in Patients with Relapsed/Refractory NeuroblastomaRelapsed/Refractory NeuroblastomaMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001042-18-BEEli Lilly and Company71
进行中（未招募）
1 期
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory NeuroblastomaPatieints with relapsed/refractory neuroblastomaJPRN-jRCT2031200270Masaki Takeshi5
进行中（未招募）
1 期
A Phase 1 Study of LY3295668 Erbumine Monotherapy and in Combination in Patients with Relapsed/Refractory NeuroblastomaEUCTR2019-001042-18-FREli Lilly and Company71
进行中（未招募）
1 期
A Phase 1 Study of LY3295668 Erbumine Monotherapy and in Combination in Patients with Relapsed/Refractory NeuroblastomaRelapsed/Refractory NeuroblastomaMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001042-18-DEEli Lilly and Company71
进行中（未招募）
1 期
A Phase 1 Study of LY3295668 Erbumine Monotherapy and in Combination in Patients with Relapsed/Refractory NeuroblastomaRelapsed/Refractory NeuroblastomaMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001042-18-GBEli Lilly and Company71